CN104277042A - Preparation method of imidazopyridine derivative - Google Patents

Preparation method of imidazopyridine derivative Download PDF

Info

Publication number
CN104277042A
CN104277042A CN201410542903.2A CN201410542903A CN104277042A CN 104277042 A CN104277042 A CN 104277042A CN 201410542903 A CN201410542903 A CN 201410542903A CN 104277042 A CN104277042 A CN 104277042A
Authority
CN
China
Prior art keywords
compound
reaction
solvent
xylol
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410542903.2A
Other languages
Chinese (zh)
Inventor
陈芳军
李书耘
邓泽平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Huateng Pharmaceutical Co Ltd
Original Assignee
Hunan Huateng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Huateng Pharmaceutical Co Ltd filed Critical Hunan Huateng Pharmaceutical Co Ltd
Priority to CN201410542903.2A priority Critical patent/CN104277042A/en
Publication of CN104277042A publication Critical patent/CN104277042A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses a preparation method of imidazopyridine derivative 2-(chloromethyl)-7-methyl-imidazo-[1,2-a] pyridine. A target product is obtained through ring closing, reduction and chlorination based on 2-amido-4-methylpyridine as an initial raw material. The compound is an important medical intermediate.

Description

A kind of preparation method of imidazopyridine derivatives
Technical field
The present invention relates to a kind of novel processing step of medicine intermediate, particularly the preparation method of a kind of imidazopyridine derivatives 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine.
Technical background
Compound 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine, structural formula is:
This compound 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine and relevant derivative has widespread use in pharmaceutical chemistry and organic synthesis.The synthesis of current 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine is comparatively difficult.Therefore, need exploitation raw material to be easy to get, easy to operate, reaction is easy to control, the synthetic method that overall yield is suitable.
Summary of the invention
The invention discloses the method that one prepares 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine, 2-AMINO-4-PICOLINE is starting raw material, and obtain target product 4 through the ring that reaches a standard, reduction, chlorination, synthetic route as shown in Figure 1.Synthesis step is as follows:
(1) be starting raw material with 2-AMINO-4-PICOLINE, obtain 2 through ring closure reaction;
(2) carry out reduction reaction 2, obtain 3;
(3) carry out chlorination reaction 3 and obtain 4;
One preferred embodiment in, described ring closure reaction is prepared compound 2 reagent used and is selected from 3-BrPA ethyl ester; The reductive agent that described reduction reaction prepares compound 3 used is selected from sodium borohydride; The chlorizating agent that described chlorination reaction prepares compound 4 used is selected from sulfur oxychloride.
One preferred embodiment in, the solvent that described ring closure reaction prepares compound 2 used is selected from glycol dimethyl ether; Described reduction reaction prepares compound 3 solvent selected from methanol used; The solvent that described chlorination reaction prepares compound 4 used is selected from toluene.
One preferred embodiment in, described ring closure reaction prepares the room temperature that compound 2 temperature of reaction used is solvent; It is room temperature that described reduction reaction prepares compound 3 temperature used; Described chlorination reaction prepare compound 4 used be the reflux temperature of solvent.
The present invention relates to the preparation method of a kind of 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine, there is no other Patents bibliographical informations at present.
Accompanying drawing explanation
Fig. 1 is the synthetic route chart of compound 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine.
The present invention is further described by the following embodiment, and these descriptions are not be further limited content of the present invention.One skilled in the art will understand that the equivalent replacement that technical characteristic of the present invention is done, or improve accordingly, still belong within protection scope of the present invention.
Specific embodiment mode
Embodiment 1
(1) synthesis of 7-methyl-imidazoles also [1,2-a] pyridine-2-ethyl formate
25g2-amino-4-methylpyridine is joined in 200ml glycol dimethyl ether, add 54g3-ethyl bromide acetone, stirred overnight at room temperature, concentrate and add ethyl acetate and water again, separatory, drying, concentrated, residuum upper prop is separated and obtains 28g7-methyl-imidazoles also [1,2-a] pyridine-2-ethyl formate.
(2) synthesis of (7-methyl-imidazoles is [1,2-a] pyridine-2-base also) methyl alcohol
26g7-methyl-imidazoles also [1,2-a] pyridine-2-ethyl formate joins in 280ml anhydrous methanol, add 17g sodium borohydride again, stirring at room temperature 2 hours, add saturated ammonium chloride, then add ethyl acetate and water, extract separatory, drying, concentrate, on residuum, silicagel column is separated to obtain 18g (7-methyl-imidazoles is [1,2-a] pyridine-2-base also) methyl alcohol.
(3) synthesis of 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine
16g (7-methyl-imidazoles also [1,2-a] pyridine-2-base) methyl alcohol joins in 190ml toluene, add 52g sulfur oxychloride again, reflux stirs 3 hours, concentrated, adds ethyl acetate and saturated sodium bicarbonate aqueous solution, extraction separatory, dry, concentrated, on residuum, silicagel column is separated to obtain 12g2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine.

Claims (6)

1. the preparation method of imidazopyridine derivatives 2-(chloromethyl)-7-methyl-imidazoles also [1,2-a] pyridine, take 2-AMINO-4-PICOLINE as starting raw material, obtain target product 4 through the ring that reaches a standard, reduction, chlorination, synthetic route is as follows.
2. method according to claim 1, it is characterized by 3 described step reactions is,
(1) be starting raw material with 2-AMINO-4-PICOLINE, obtain 2 through ring closure reaction;
(2) carry out reduction reaction 2, obtain 3;
(3) carry out chlorination reaction 3 and obtain 4;
3. according to the method for claim 1-2, it is characterized in that, described ring closure reaction is prepared compound 2 reagent used and is selected from 3-BrPA ethyl ester; Described reduction reaction is prepared compound 3 reductive agent used and is selected from the mixture of one or more in sodium borohydride, POTASSIUM BOROHYDRIDE, lithium borohydride, sodium cyanoborohydride, lithium aluminium hydride, borine; Described chlorination reaction is prepared compound 4 chlorizating agent used and is selected from the mixture of one or more in chlorine, hydrogenchloride, sulfur oxychloride, phosphorus trichloride, phosphorus oxychloride.
4. according to the method for claim 1-2, it is characterized in that, described ring closure reaction prepares compound 2 solvent selected from methanol used, ethanol, n-propyl alcohol, Virahol, tetrahydrofuran (THF), methylene dichloride, toluene, o-Xylol, p-Xylol, m-xylene, N, the mixture of one or more in dinethylformamide, N,N-dimethylacetamide, glycol dimethyl ether; Described reduction reaction prepares compound 3 solvent selected from methanol used, ethanol, n-propyl alcohol, Virahol, tetrahydrofuran (THF), methylene dichloride, toluene, o-Xylol, p-Xylol, m-xylene, N, the mixture of one or more in dinethylformamide, N,N-dimethylacetamide, water; Described chlorination reaction prepares compound 4 solvent selected from methanol used, ethanol, n-propyl alcohol, Virahol, tetrahydrofuran (THF), methylene dichloride, toluene, o-Xylol, p-Xylol, m-xylene, N, the mixture of one or more in dinethylformamide, N,N-dimethylacetamide.
5. according to the method for claim 1-2, it is characterized in that, described ring closure reaction prepares the reflux temperature that compound 2 temperature of reaction used is 0 DEG C ~ solvent; Described reduction reaction prepares the reflux temperature that compound 3 temperature used is 0 DEG C ~ solvent; Described chlorination reaction prepare compound 4 used be the reflux temperature of 0 DEG C ~ solvent.
6. according to the method for claim 1-2, it is characterized in that, it is room temperature that described ring closure reaction prepares compound 2 temperature of reaction used; It is room temperature that described reduction reaction prepares compound 3 temperature used; Described chlorination reaction prepare compound 4 used be the reflux temperature of solvent.
CN201410542903.2A 2014-10-15 2014-10-15 Preparation method of imidazopyridine derivative Pending CN104277042A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410542903.2A CN104277042A (en) 2014-10-15 2014-10-15 Preparation method of imidazopyridine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410542903.2A CN104277042A (en) 2014-10-15 2014-10-15 Preparation method of imidazopyridine derivative

Publications (1)

Publication Number Publication Date
CN104277042A true CN104277042A (en) 2015-01-14

Family

ID=52252439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410542903.2A Pending CN104277042A (en) 2014-10-15 2014-10-15 Preparation method of imidazopyridine derivative

Country Status (1)

Country Link
CN (1) CN104277042A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104557926A (en) * 2015-01-30 2015-04-29 何思伟 Synthesis method of 3-substituted imidazopyridine compound as medical intermediate
CN104628721A (en) * 2015-01-22 2015-05-20 湖南华腾制药有限公司 Preparation method of imidazo [1, 2-a] pyridine derivative
CN107286154A (en) * 2016-04-05 2017-10-24 湖南华腾制药有限公司 A kind of preparation method of fluorine-containing imidazopyridine derivatives
CN107400127A (en) * 2016-05-20 2017-11-28 湖南华腾制药有限公司 A kind of preparation method of fluorine-containing imidazopyridine derivatives
CN107698583A (en) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 A kind of preparation method of imidazopyridine derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056220A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
CN101006078A (en) * 2004-06-17 2007-07-25 惠氏公司 Gonadotropin releasing hormone receptor antagonists
CN103421005A (en) * 2012-05-16 2013-12-04 上海医药集团股份有限公司 Acetylene derivative capable of resisting activity of tumor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101006078A (en) * 2004-06-17 2007-07-25 惠氏公司 Gonadotropin releasing hormone receptor antagonists
WO2007056220A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
CN103421005A (en) * 2012-05-16 2013-12-04 上海医药集团股份有限公司 Acetylene derivative capable of resisting activity of tumor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUANGXIN XIA等: "Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 15, no. 11, 2 June 2005 (2005-06-02), pages 2790 - 2794 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628721A (en) * 2015-01-22 2015-05-20 湖南华腾制药有限公司 Preparation method of imidazo [1, 2-a] pyridine derivative
CN104557926A (en) * 2015-01-30 2015-04-29 何思伟 Synthesis method of 3-substituted imidazopyridine compound as medical intermediate
CN104557926B (en) * 2015-01-30 2016-06-22 深圳市祥根生物科技有限公司 A kind of synthetic method of medicine intermediate 3-substituted imidazole pyridine compounds and their
CN107286154A (en) * 2016-04-05 2017-10-24 湖南华腾制药有限公司 A kind of preparation method of fluorine-containing imidazopyridine derivatives
CN107400127A (en) * 2016-05-20 2017-11-28 湖南华腾制药有限公司 A kind of preparation method of fluorine-containing imidazopyridine derivatives
CN107698583A (en) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 A kind of preparation method of imidazopyridine derivatives

Similar Documents

Publication Publication Date Title
CN104292145A (en) Preparation method of 6-bromoindole derivative
CN104262257A (en) Preparation method of pyrazole derivative
CN104277042A (en) Preparation method of imidazopyridine derivative
CN104230853B (en) A kind of preparation method of (p-methylphenyl) methylamine-N-ethylmorpholine hydrochloride
CN104292179A (en) Preparation method of 2-chlorobenzo[d]oxazole-5-formaldehyde
CN104926775A (en) Preparation method of fluorine-containing pyran derivative
CN104387367A (en) Method for preparing disubstituted benzimidazole derivative
CN104311544A (en) Preparation method of benzoxazole derivative
CN104829581A (en) Preparation method of 6-bromo pyran derivative
CN104860910A (en) Preparation method of 8-fluoropyran derivative
CN104829576A (en) Preparation method of 7-fluoropyran derivatives
CN104829574A (en) 8-bromo pyran derivative preparation method
CN104628721A (en) Preparation method of imidazo [1, 2-a] pyridine derivative
CN104844549A (en) Preparation method of 7 - bromine pyran derivatives
CN104326977A (en) Preparation method of 6,7-diethyl-4-hydroxyquinoline
CN104402880A (en) Preparation method of imidazopyridine derivative
CN104311547A (en) Preparation method of thiazole derivative
CN104262281A (en) Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole
CN104292213A (en) Preparation method of pyrimidine derivative
CN104250233B (en) A kind of preparation method of 4-tertbutyloxycarbonyl-2-cyclopropyl morpholine
CN104292157A (en) Preparation method of 1-(quinoline-4-yl) ethylamine
CN104327029A (en) Preparation method of oxygen-containing heterocyclic compound
CN104447567B (en) A kind of preparation method of 1 substituted benzimidazole derivant
CN104311491A (en) Preparation method of benzimidazole derivative
CN104557925A (en) Preparation method of pyrazolopyridine derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150114